Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, Cédric, Blay, Jean-Yves, Borg, Christophe, Michiels, Stefan, Ghiringhelli, François, Robert, Caroline, Nonn, Céline, Chaput, Nathalie, Taïeb, Julien, Delahaye, Nicolas F., Flament, Caroline, Emile, Jean-François, Le Cesne, Axel, Zitvogel, Laurence · 2009 · Cancer Research

Abstract

Clinical outcomes of gastrointestinal stromal tumor (GIST)-bearing patients treated with imatinib mesylate (IM) are variable. Other than the site of mutation within the c-kit gene, prognostic features of GIST remain undefined. IM can exhibit off-target effects such as triggering natural killer (NK) cell activity. We addressed whether NK cell functions could predict long term survival with IM. NK cell functions were followed up in 77 GIST patients enrolled onto two phase III trials. "Immunologic responders" were defined as patients whose NK cell IFN-gamma values after 2 months of IM were higher than or equal to the baseline value at entry into the trial. The prognostic effect of IFN-gamma on progression-free survival was assessed by a Wald test in a Cox regression analysis using the landmark method and stratified by trial and on the c-kit mutational status. Fifty-six patients were evaluable for the NK cell IFN-gamma responses at baseline and 2 months. Their median follow-up for progression-free survival was 3.7 years. Thirty-four of 56 patients were immunologic responders to IM. In the Cox regression analysis, immunologic responders possessed a hazard ratio of progression or death equal to 0.29 (95% confidence interval, 0.12-0.70; P = 0.006) compared with nonresponders. Kaplan-Meier 2-year survival estimates were 85% for immunologic responders and 50% for nonresponders. Moreover, the immunologic response added prognostic value to the c-kit mutation. The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-3807

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 202

Metadata

Authors
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., Flament, C., Emile, J.-F., Le Cesne, A., & Zitvogel, L.
Affiliations
  • 1Institut National de la Santé Et de la Recherche Médicale (INSERM), Unit U805 "Tumor immunology and immunotherapy,"
  • Centre Léon Bérard (FR)
  • Inserm (FR)
  • 3Statistics,
  • 4Medicine, Dermatology Unit, and
  • 7Department of Pathology and INSERM U602, Hôpital Ambroise Paré, Boulogne, France; and
  • 5Medicine, Institut Gustave Roussy, Villejuif, France;
  • Université Paris-Sud (FR)
Venue
Cancer Research
Published
2009-04-15
Volume
69
Issue
8
Pages
3563-3569
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1964703707
Cited by
202
References
47
Citations by year
2026: 3 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 10 · 2021: 7 · 2020: 17 · 2019: 7 · 2018: 7 · 2017: 15 · 2016: 14 · 2015: 17 · 2014: 20 · 2013: 24 · 2012: 17
FWCI
12.70
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
gastrointestinal stromal tumor, imatinib mesylate, natural killer cells, interferon-gamma, immune response, prognostic factors, progression-free survival, KIT mutations, long-term survival
MeSH terms
Imatinib Mesylate, Antineoplastic Agents, Benzamides, Dendritic Cells, Exons, Female, Humans, Interferon-gamma, Interleukin-2, Killer Cells, Natural, Male, Middle Aged, Piperazines, Pyrimidines, Proto-Oncogene Proteins c-kit, Gastrointestinal Stromal Tumors, Natural Cytotoxicity Triggering Receptor 3, NK Cell Lectin-Like Receptor Subfamily K

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-3807
The paper
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., Flament, C., Emile, J.-F., Le Cesne, A., & Zitvogel, L. (2009). Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-3807

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.